Prexige Still Postponed: Novartis To Resubmit COX-2 Inhibitor In U.S. In 2007
Executive Summary
Novartis plans to resubmit Prexige (lumiracoxib) in the U.S. in the first half of 2007; approval of the oral COX-2 inhibitor in the European Union and Canada for treatment of osteoarthritis symptoms was announced Nov. 7